1
Mochida Ei C O Mochida Pharmac: Reaction vessel.. Mochida Pharm, June 5, 1991: EP0430248-A2 (87 worldwide citation)

A reaction vessel for microassay is provided. The reaction vessel comprises a body structure having provided therein at least one reaction unit comprising a channel having at least one fluid inlet and at least one reagent-immobilized area in the downstream of the fluid inlet. The channel is provided ...


2
Mochida Ei, Kudo Takashi, Sugawara Toshiyuki, Tsumura Minoru: Immunoassay vessel conveying analysis information. Mochida Pharm, May 16, 1984: GB2129551-A (69 worldwide citation)

A vessel for use in an immunoassay and containing an insolubilised antibody and a labelled antibody carries also information required for the immunoassay, such as sample information and details concerning the equation defining the calibration curve, whereby the immunoassay can be quickly and accurat ...


3
Terao Toshihiko, Kanayama Naohiro: External preparation for skin protection. Mochida Pharm, October 23, 1996: EP0738516-A1 (49 worldwide citation)

The present invention relates to a dermatological agent for skin protection characterized by its inclusion of ulinastatin which is effective in preventing skin dryness, skin keratosis and skin aging, and in treating acne vulgaris and atopic dermatitis, and the like. The dermatological agent for skin ...


4
Nagata Shigekazu, Suda Takashi, Takahashi Tomohiro C O Mochida, Nakamura Norio C O Mochida Pha: A fas ligand, a fragment thereof and dna encoding the same.. Mochida Pharm, Osaka Bioscience Inst, October 4, 1995: EP0675200-A1 (32 worldwide citation)

This invention provides a novel polypeptide useful in the field of medicines, a novel DNA which encodes the novel polypeptide, a recombinant DNA molecule which contains the novel DNA, a transformant transformed with the novel DNA or the recombinant DNA molecule, a process for the purification of the ...


5
Ohnishi Haruo, Kosuzume Hiroshi, Mizota Masahiro, Suzuki Yasuo, Mochida Ei: Cephalosporin derivatives, processes for producing the same and compositions containing them.. Mochida Pharm, August 7, 1985: EP0150507-A2 (29 worldwide citation)

Novel cephalosporin derivatives, processes for preparing thereof, compositions for preventing and/or treating infectious diseases which comprise the novel cephalosporin derivatives as active components, and the intermediate compounds in synthesis of cephalosporin derivative and processes for produci ...


6
Yokoyama Mitsuhiro, Origasa Hideki, Matsuzaki Masunori, Matsuzawa Yuji, Saito Yasushi: Composition for preventing the occurrence of cardiovascular event in multiple risk patient. Mochida Pharm, February 11, 2009: EP2022495-A1 (29 worldwide citation)

Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG ...


7
Ichimura Michio, Ohta Hidemi, Sakai Kiyoshi, Kunihiro Yasuyuki, Nakashiro Takehisa: Thrombolytic composition and a process for production thereof.. Mochida Pharm, April 8, 1987: EP0217379-A2 (27 worldwide citation)

The present invention is directed to a thrombolytic composition comprising tissue plasminogen activator and arginine or an acid addition salt thereof. Arginine or an acid addition salt thereof can increase the solubility of the tissue plasminogen activator, and thus the tissue plasminogen activator ...


8
Inoue Keizo, Arai Hiroyuki, Aoki Junken: Novel lipase. Mochida Pharm, April 2, 2003: EP1298205-A1 (25 worldwide citation)

(57) Abstrict: A novel phospholipase A1 (PLA1) having a substrate specificity to phosphatidic acid (PA); a peptide or a polypeptide originating in the above novel PLA1; a polynucleotide encoding the peptide or polypeptide originating in the novel PLA1; a process for producing the peptide or polypept ...


9
Shimano Hitoshi, Kato Toyonori: Remedial agent for fat toxicity. Mochida Pharm, September 19, 2007: EP1834639-A1 (20 worldwide citation)

In view of the situation that a clinically acceptable medical agent which has the action of preventing and relieving the lipotoxicity with no significant side effects is not yet provided, such medical agent is provided. An agent for relieving lipotoxicity which comprises an unsaturated fatty acid co ...


10
Yamauchi Tadakazu, Kanamori Toshinori, Nobuhara Masahiro: Process and device for specific binding assay.. Mochida Pharm, February 3, 1993: EP0525723-A2 (19 worldwide citation)

A specific binding assay process which is useful for quick qualitative or quantitative measurement and can be used for various purposes, and a specific binding assay device suitable for the practice of the process, in which a substance to be assayed in a liquid test sample is determined qualitativel ...